ARMATA PHARMACEUTICALS INC
NYSE: ARMP (Armata Pharmaceuticals, Inc.)
Kemas kini terakhir: semalam, 10:34PM7.58
0.11 (1.47%)
| Penutupan Terdahulu | 7.47 |
| Buka | 7.33 |
| Jumlah Dagangan | 75,836 |
| Purata Dagangan (3B) | 62,731 |
| Modal Pasaran | 278,267,936 |
| Harga / Buku (P/B) | 2.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2026 |
| Margin Keuntungan | -9.07% |
| Margin Operasi (TTM) | -1,668.23% |
| EPS Cair (TTM) | -0.400 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -49.20% |
| Nisbah Semasa (MRQ) | 0.120 |
| Aliran Tunai Operasi (OCF TTM) | -34.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.48 M |
| Pulangan Atas Aset (ROA TTM) | -24.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Armata Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 69.55% |
| % Dimiliki oleh Institusi | 2.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Madison Asset Management, Llc | 31 Mar 2026 | 2,107,675 |
| Dauntless Investment Group, Llc | 31 Mar 2026 | 90,580 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |